It indicates that the doxorubicin induces the dysregulation of hiPSC-CMs derived RAD9A, HSPA1B, GATA2, IGF2R, CD200, ERCC8, and BCL11A genes that are associated with the pathogenesis of doxorubicin-induced cardiotoxicity in breast cancer patients. Here, RAD9A is linked to breast cancer.